whitepaper

Catalogue: Resources for COVID-19 and influenza vaccine development

Posted: 18 June 2021 | | No comments yet

A panel of SARS-CoV-2 reagents (e.g. antigens, antibodies, and kits) and influenza antigens have been developed to support the development of vaccines.

To support the development of COVID-19 and influenza vaccine, Sino Biological has developed a large collection of SARS-CoV-2 reagents, including recombinant antigens, recombinant mutants, neutralising antibodies, and specific antibodies as well as 630+ HA, NA, and ME antigens from over 250 strains of influenza viruses, including vaccine strains and the pandemic strains.












    To read this catalogue in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Sino Biological

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend